Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

EVALUATION OF SHORT-TERM AND LONG-TERM TREATMENT OF NARCOLEPSY SYNDROME WITH CLOMIPRAMINE HYDROCHLORIDE ACTA NEUROLOGICA SCANDINAVICA Guilleminault, C., RAYNAL, D., Takahashi, S., Carskadon, M., Dement, W. 1976; 54 (1): 71-87

Abstract

Clinical examinations, questionnaires, and 24- or 36-hour polygraphic recordings were performed on 21 adult patients with the narcolepsy syndrome to investigate the short- and long-term effects of clomipramine HCL. Cataplexy was improved by the medication, but tolerance was observed 4 1/2 months of treatment. Clomipramine HCL induced significant changes in the sleep EEG, chin EMG, and EOG. In two patients, clomipramine HCL caused a nocturnal myoclonia that produced insomnia. Sexual side effects were seen with clomipramine HCL, particularly in males. A combination of clomipramine HCL and L-Dopa apparently prevented this difficulty in one patient. A rebound of cataplexy was seen during the 15 days following withdrawal of the drug. Methysergide maleate was found to be ineffective on cataplexy in four patients.

View details for Web of Science ID A1976BT79800006

View details for PubMedID 936975